Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Cash from Investing Activities for 7 consecutive years, with -$134000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 53.63% year-over-year to -$134000.0, compared with a TTM value of -$1.6 million through Dec 2025, up 19.68%, and an annual FY2025 reading of -$1.6 million, up 19.68% over the prior year.
  • Cash from Investing Activities was -$134000.0 for Q4 2025 at Keros Therapeutics, down from -$132000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$132000.0 in Q3 2025 and bottomed at -$1.1 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is -$410550.0, with a median of -$331000.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities crashed 1721.43% in 2021, then soared 65.8% in 2025.
  • Year by year, Cash from Investing Activities stood at -$159000.0 in 2021, then plummeted by 120.75% to -$351000.0 in 2022, then crashed by 54.13% to -$541000.0 in 2023, then skyrocketed by 46.58% to -$289000.0 in 2024, then surged by 53.63% to -$134000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for KROS at -$134000.0 in Q4 2025, -$132000.0 in Q3 2025, and -$720000.0 in Q2 2025.